Modalités de l’utilisation de l’alpha-glucosidase recombinante humaine (Myosine TM) et du suivi des patients adultes

Annane D, Caillaud C, Laforêt P, Maire I, Nicolino M, Orlikovski D.
 Recommandations du Comité d’Evaluation du traitement de la maladie de Pompe 2008.
 In adult Pompe disease, it is recommended to assess patients by MFM initially and every 6 months or annually by the reference center for the patient in the monitoring of the Myosine protocol. (in French).

Keywords : Pompe disease, Myosyme, recommendations, protocol, clinical trials

 

Articles dans les revues scientifiques

Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients.

D'Angelo MG, Gandossini S, Martinelli Boneschi F, Sciorati C, Bonato S, Brighina E, Comi GP, Turconi AC, Magri F, Stefanoni G, Brunelli S, Bresolin N, Cattaneo D, Clementi E. Pharmacol Res. 2012. 65(4): 472-9. The main of this monocentric pilot study was to evaluate...

read more